SOX11 expression in mantle cell lymphoma

Leukemia and Lymphoma

Volumn 51, Issue 11, 2010, Pages 1962-1967

  Xu, Wei ^a   Li, Jian Yong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

cyclin D1; Mantle cell lymphoma; SOX11

Indexed keywords

CYCLIN D1; MESSENGER RNA; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR SOX; TRANSCRIPTION FACTOR SOX10; TRANSCRIPTION FACTOR SOX11; TRANSCRIPTION FACTOR SOX12; TRANSCRIPTION FACTOR SOX13; TRANSCRIPTION FACTOR SOX14; TRANSCRIPTION FACTOR SOX15; TRANSCRIPTION FACTOR SOX17; TRANSCRIPTION FACTOR SOX18; TRANSCRIPTION FACTOR SOX21; TRANSCRIPTION FACTOR SOX30; TRANSCRIPTION FACTOR SOX4; TRANSCRIPTION FACTOR SOX5; TRANSCRIPTION FACTOR SOX6; TRANSCRIPTION FACTOR SOX7; TRANSCRIPTION FACTOR SOX8; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTION FACTOR SOXA; TRANSCRIPTION FACTOR SOXG; TRANSCRIPTION FACTOR SOXH; UNCLASSIFIED DRUG;

BURKITT LYMPHOMA; CANCER SURVIVAL; CHROMOSOME 2P; HAIRY CELL LEUKEMIA; HUMAN; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, MANTLE-CELL; SOX TRANSCRIPTION FACTORS; SOXC TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649312942     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.514968     Document Type: Review

References (54)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
2. Li JY, Gaillard F, Moreau A, et al. Detection of translocation t (11;14) (q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol 1999;154:1449-1452.
3. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005;106:4315-4321.
4. Islam TC, Asplund AC, Lindvall JM, et al. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of cyclin D1 in mantle cell lymphoma. Leukemia 2003;17:1880-1890.
5. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-197.
6. Sander B, Flygare J, Porwit-Macdonald A, et al. Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1. Int J Cancer 2005;117:418-430.
7. Salaverria I, Zettl A, Beà S, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007;25:1216-1222.
8. Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t (11;14)-negative mantle cell lymphomas. Blood 2008;111:5683-5690.
9. Gesk S, Klapper W, Martín-Subero JI, et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood 2006;108:1109-1110.
10. Herens C, Lambert F, Quintanilla-Martinez L, Bisig B, Deusings C, de Leval L. Cyclin D1-negative mantle cell lymphoma with cryptic t (12;14) (p13;q32) and cyclin D2 overexpression. Blood 2008;111:1745-1746.
11. Ek S, Dictor M, Jerkeman M, Jirström K, Borrebaeck CA. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008;111:800-805.
12. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:1555-1562.
13. Wang X, Asplund AC, Porwit A, et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol 2008;143:248-252.
14. Dictor M, Ek S, Sundberg M, et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica 2009;94:1563-1568.
15. Chen YH, Gao J, Fan G, Peterson LC. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t (11;14) (q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol 2010;23:105-112.
16. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 1999;27:1409-1420.
17. Kiefer JC. Back to basics: Sox genes. Dev Dyn 2007;236:2356-2366.
18. Lefebvre V, Dumitriu B, Penzo-Méndez A, Han Y, Pallavi B. Control of cell fate and differentiation by Sry-related highmobility-group box (Sox) transcription factors. Int J Biochem Cell Biol 2007;39:2195-2214.
19. Guth SI, Wegner M. Having it both ways: Sox protein function between conservation and innovation. Cell Mol Life Sci 2008;65:3000-3018.
20. Harley VR, Lovell-Badge R, Goodfellow PN. Definition of a consensus DNA binding site for SRY. Nucleic Acids Res 1994;22:1500-1501.
21. Werner MH, Huth JR, Gronenborn AM, Clore GM. Molecular basis of human 46X, Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex. Cell 1995;81:705-714.
22. Dong C, Wilhelm D, Koopman P. Sox genes and cancer. Cytogenet Genome Res 2004;105:442-447.
23. Jay P, Gozé C, Marsollier C, et al. The human SOX11 gene: cloning, chromosomal assignment and tissue expression. Genomics 1995;29:541-545.
24. Dy P, Penzo-Méndez A, Wang H, Pedraza CE, Macklin WB, Lefebvre V. The three SoxC proteins - Sox4, Sox11 and Sox12 - exhibit overlapping expression patterns and molecular properties. Nucleic Acids Res 2008;36:3101-3117.
25. Penzo-Méndez AI. Critical roles for SoxC transcription factors in development and cancer. Int J Biochem Cell Biol 2010;42:425-428.
26. Lee CJ, Appleby VJ, Orme AT, Chan WI, Scotting PJ. Differential expression of SOX4 and SOX11 in medulloblastoma. J Neurooncol 2002;57:201-214.
27. Weigle B, Ebner R, Temme A, et al. Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. Oncol Rep 2005;13:139-144.
28. Hargrave M, Wright E, Kun J, Emery J, Cooper L, Koopman P. Expression of the Sox11 gene in mouse embryos suggests roles in neuronal maturation and epithelio-mesenchymal induction. Dev Dyn 1997;210:79-86.
29. Sock E, Rettig SD, Enderich J, Bösl MR, Tamm ER, Wegner M. Gene targeting reveals a widespread role for the highmobility-group transcription factor Sox11 in tissue remodeling. Mol Cell Biol 2004;24:6635-6644.
30. Cheung M, Abu-Elmagd M, Clevers H, Scotting PJ. Roles of Sox4 in central nervous system development. Brain Res Mol Brain Res 2000;79:180-191.
31. Bergsland M, Werme M, Malewicz M, Perlmann T, Muhr J. The establishment of neuronal properties is controlled by Sox4 and Sox11. Genes Dev 2006;20:3475-3486.
32. Jankowski MP, Cornuet PK, McIlwrath S, Koerber HR, Albers KM. SRY-box containing gene 11 (Sox11) transcription factor is required for neuron survival and neurite growth. Neuroscience 2006;143:501-514.
33. van de Wetering M, Oosterwegel M, van Norren K, Clevers H. Sox-4, an Sry-like HMG box protein, is a transcriptional activator in lymphocytes. EMBO J 1993;12:3847-3854.
34. Schilham MW, Oosterwegel MA, Moerer P, et al. Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature 1996;380:711-714.
35. Smith E, Sigvardsson M. The roles of transcription factors in B lymphocyte commitment, development, and transformation. J Leukoc Biol 2004;75:973-981.
36. Pascual V, Liu YJ, Banchereau J. Normal human B cell subpopulations and their malignant counterparts. Baillieres Clin Haematol 1997;10:525-538.
37. Capello D, Gaidano G. Molecular pathophysiology of indolent lymphoma. Haematologica 2000;85:195-201.
38. Walsh SH, Thorsélius M, Johnson A, et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 2003;101:4047-4054.
39. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750-762.
40. Beà S, Ribas M, Hernández JM, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999;93:4365-4374.
41. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007;109:271-280.
42. Katzenberger T, Kienle D, Stilgenbauer S, et al. Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. Br J Haematol 2008;142:538-550.
43. Salaverria I, Espinet B, Carrió A, et al. Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes Cancer 2008;47:1086-1097.
44. Sander S, Bullinger L, Leupolt E, et al. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. Haematologica 2008;93:680-687.
45. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 2000;95:2253-2261.
46. Ek S, Högerkorp CM, Dictor M, Ehinger M, Borrebaeck CA. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 2002;62:4398-4405.
47. Ek S, Andréasson U, Hober S, et al. From gene expression analysis to tissue microarrays: a rational approach to identify therapeutic and diagnostic targets in lymphoid malignancies. Mol Cell Proteomics 2006;5:1072-1081.
48. Sara E, Borrebaeck CA. Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice. Curr Genomics 2007;8:171-179.
49. Rizzatti EG, Falcão RP, Panepucci RA, et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 2005;130:516-526.
50. Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 2008;121:3853-3857.
51. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-345.
52. Sinner D, Kordich JJ, Spence JR, et al. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol 2007;27:7802-7815.
53. Troussard X, Avet-Loiseau H, Macro M, et al. Cyclin D1 expression in patients with multiple myeloma. Hematol J 2000;1:181-185.
54. Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408-1418.